Strategic Funding Vicinitas has secured a $65M Series A, signaling strong investor confidence and a readiness to scale operations, which presents opportunities to engage potential collaborators, partners, or contract research organizations to accelerate development timelines.

Targeted Therapy Focus The company specializes in Deubiquitinase Targeting Chimeras (DUBTACs) to stabilize disease-relevant proteins, offering a unique value proposition for pharmaceutical partners seeking to address previously undruggable targets across oncology and monogenic diseases.

Early Stage, Strategic Partnerships Spun out from Novartis Institutes for BioMedical Research and UC Berkeley, Vicinitas has a credible academic-industry pedigree that can facilitate collaboration opportunities with large pharma, academic consortia, and early-access programs.

Market Readiness With revenue under one million but substantial funding, the company is positioned for partnering discussions around co-development, licensing, or technology integration to bring DUBTAC-based therapies to clinical evaluation sooner.

Technical Enablement Their tech stack and digital presence indicate scalable capabilities for partner engagements, including CRM readiness, cloud-based data handling, and digital engagement, enabling efficient outreach and collaboration workflows.